AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AstraZeneca's Price Target Raised to $97 by Berenberg Analysts
ByAinvest
Wednesday, Jul 9, 2025 10:18 pm ET1min read
Berenberg analyst Luisa Hector raised AstraZeneca's price target to $97 from $93 and kept a Buy rating, citing substantial pipeline progress and increasing the 2030 revenue forecast by 3% to $79B, ahead of consensus. The analyst believes AstraZeneca shares should price in a larger pipeline valuation.
Berenberg analyst Luisa Hector recently raised AstraZeneca's (AZN) price target to $97 from $93, maintaining a Buy rating on the shares. The analyst cited substantial pipeline progress and increased the 2030 revenue forecast by 3% to $79 billion, surpassing consensus estimates [1].The analyst highlighted that AstraZeneca's shares should reflect a larger pipeline valuation, indicating that the company's ongoing advancements in its drug portfolio are being undervalued. The updated revenue forecast underscores the analyst's confidence in AstraZeneca's ability to deliver strong financial performance over the next decade.
AstraZeneca's shares have been trading at around $70.82, and the current analyst consensus price target stands at $84.18, with a high of $97.00. The company's earnings per share (EPS) estimates for the current quarter are expected to be $1.13, with a range of $1.07 to $1.20 [2].
The recent price target increase comes amidst a broader market focus on AstraZeneca's strategic moves, including potential deals and market expansions. The company has been exploring a deal with Summit Therapeutics, which could add significant value to its oncology portfolio, and rumors about a U.S. stock listing are also circulating [3].
Investors should closely monitor AstraZeneca's pipeline progress and the potential outcomes of these strategic initiatives. The company's strong dividend history and relatively low valuation compared to peers like Roche and Merck make it an attractive investment opportunity for long-term investors.
References:
[1] https://www.tipranks.com/news/the-fly/astrazeneca-price-target-raised-to-97-from-93-at-berenberg-thefly
[2] https://finance.yahoo.com/quote/AZN/analysis/
[3] https://www.ainvest.com/news/astrazeneca-dip-golden-buying-opportunity-oncology-innovation-2507/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet